Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 4Waldenstrom Macroglobulinemia 1Lymphoma, Mantle-Cell 1

Interventions

Rituximab 99Cyclophosphamide 63fludarabine phosphate 55Peripheral Blood Stem Cell Transplantation 52Mycophenolic Acid 34Whole-Body Irradiation 33Bortezomib 33ibrutinib 29Dexamethasone 27Tacrolimus 26Cyclosporine 25Busulfan 23Etoposide 22Melphalan 20Filgrastim 20zanubrutinib 18Methotrexate 18Lenalidomide 18Antilymphocyte Serum 18Radiotherapy 16Bendamustine Hydrochloride 14Sirolimus 13Calcium Dobesilate 11Flow Cytometry 10Everolimus 10venetoclax 9ibritumomab tiuxetan 9Prednisone 9Indium 9Cyclosporins 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Waldenstrom Macroglobulinemia × antineoplaston A10 × Lymphoid × Clear all
NCT00003512 2018-02-05

Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia

Burzynski Research Institute

Phase 2 Withdrawn
Lymphoid

Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡